Revenue
2022
2023
2024
2025
Actuate Therapeutics, Inc. (ACTU)
Price$0.9974Cached quote
Net income
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research & development | $10.3M | $18.7M | $21.7M | $16.4M |
| Operating expenses | $22.5M | $25.2M | $25.0M | $20.2M |
| Operating income | −$22.5M | −$25.2M | −$25.0M | −$20.2M |
| EBITDA | −$22.2M | −$27.3M | −$24.7M | −$20.1M |
| Net income | −$22.2M | −$27.3M | −$24.7M | −$20.2M |
| Basic EPSper basic share | -$1.06 | -$3.26 | -$17.24 | -$1.34 |
| Diluted EPSper diluted share | -$1.06 | -$3.26 | -$17.24 | -$1.34 |
Owners
Reported shareholders
≈42.46%of listed shares
BIOS Fund II, LP / BIOS Fund I QP, LP / Bios Equity Partners, LP / BIOS Fund II QP, LP / BIOS Fund I, LP / Cavu Management, LP / Bios Equity Partners II, LP / Kreis Leslie W. / BIOS Fund II NT, LP / Cavu Advisors, LLC10.2M shares · Jun 27, 2025
View holders
| Holder | % owned |
|---|---|
BIOS Fund II, LP / BIOS Fund I QP, LP / Bios Equity Partners, LP / BIOS Fund II QP, LP / BIOS Fund I, LP / Cavu Management, LP / Bios Equity Partners II, LP / Kreis Leslie W. / BIOS Fund II NT, LP / Cavu Advisors, LLC | ≈42.46%10.2M shares |
Bios Equity COF, LP / Bios Clinical Opportunity Fund, LP / Bios 2024 Co-Invest, LP / BP Directors, LP | ≈42.46%10.2M shares |
BIOS Capital Management, LP | 41.85%10.05M shares |
THOMSON TODD S / Kairos Venture Partners II, L.P. | ≈9.80%2.35M shares |
Voss Capital, LP | 7.18%1.73M shares |
SCHMITT DANIEL M | ≈3.25%780.92K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.64%393.43K shares |
AQR CAPITAL MANAGEMENT LLC | 0.53%127.49K shares |
Mazar Andrew Paul | ≈0.53%127.25K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.47%112.55K shares |
Texas Capital Bank Wealth Management Services Inc | 0.43%102.61K shares |
Palogic Value Management, L.P. | 0.42%100K shares |
MILLENNIUM MANAGEMENT LLC | 0.40%96.68K shares |
BlackRock, Inc. | 0.37%90.04K shares |
Zabrowski Dan | ≈0.32%76.35K shares |
ABS Investment Management LLC | 0.30%73.19K shares |
ABS Direct Equity Fund LLC | 0.30%73.19K shares |
VANGUARD FIDUCIARY TRUST CO | 0.23%54.5K shares |
Rock Creek Group LLC | 0.16%39.26K shares |
JANE STREET GROUP, LLC | 0.16%39.13K shares |
Percentages use 24.01M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 5, 2026Form 4 | THOMSON TODD S +1Director,TenPercentOwner | SellCommon Stock · indirect | 280.0K | $5.80 | $1.62M | 904.8K |
| Jun 27, 2025Form 4 | Bios Equity COF, LP +3Director,TenPercentOwner | BuyCommon Stock · indirect | 71.4K | $7.00 | $500.0K | 196.4K |
| Jun 27, 2025Form 4 | Bios Equity COF, LP +3Director,TenPercentOwner | BuyWarrant (Right to Buy) · derivative · indirect | 71.4K | $0.00 | $0.00 | 71.4K |
| Jun 27, 2025Form 4 | BIOS Fund II, LP +9Director,TenPercentOwner | BuyCommon Stock · indirect | 71.4K | $7.00 | $500.0K | 196.4K |
| Jun 27, 2025Form 4 | BIOS Fund II, LP +9Director,TenPercentOwner | BuyWarrant (Right to Buy) · derivative · indirect | 71.4K | $0.00 | $0.00 | 71.4K |